Pediapharm Nabs Health Canada Approval for Bacterial Ear Infection Treatment

December 19, 2016

Pediapharm received Health Canada's marketing approval for Otixal to treat a bacterial infection of the middle ear in children.

The approval was based on two multicenter, randomized, double-blind Phase III trials, the Otixal treatment arms stopped ear discharge in shorter times than the ciprofloxacin and fluocinolone acetonide alone arms.

Pediapharm intends to launch Otixal in early 2017.

View today's stories